Assess, in Young Children, the Efficacy in Preventing Acute Otitis Media of GSK Biologicals Undecavalent Pneumococcal-Protein D Conjugate Vaccine, When Administered as a Three Dose Primary Vaccination Course During the First Year of Life With a Booster Dose in the Second Year of Life.

Trial Profile

Assess, in Young Children, the Efficacy in Preventing Acute Otitis Media of GSK Biologicals Undecavalent Pneumococcal-Protein D Conjugate Vaccine, When Administered as a Three Dose Primary Vaccination Course During the First Year of Life With a Booster Dose in the Second Year of Life.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Pneumococcal 11-valent vaccine conjugate (Primary) ; Hepatitis A vaccine inactivated; Hepatitis B vaccine recombinant; Pneumococcal vaccine
  • Indications Hepatitis A; Hepatitis B; Otitis media; Pneumococcal infections
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms POET
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top